COMMUNIQUÉS West-GlobeNewswire

Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
25/03/2025
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announces that its chief [...]
Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Alzheimer’s Disease to take Place at Massachusetts General Hospital
25/03/2025
Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in Alzheimer’s subjects ATLANTA, March 25, 2025 ( [...]
Enovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025
25/03/2025
Alongside an evidence-based portfolio, Enovis will showcase how it’s “Redefining Every Step” with confidence-building education and a partnership that goes beyond the product; attendees invited to exclusive events. [...]
First Patient Dosed in Immutep’s TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer
25/03/2025
First patient safely dosed at Calvary Mater Newcastle Hospital in Australia, marking a significant milestone for Immutep Global Phase III with efti will enrol approximately 756 patients at more than 150 clinical sites [...]
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program
25/03/2025
MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as [...]
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)
25/03/2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral [...]
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025
25/03/2025
CAMBRIDGE, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced [...]
Prime Biome Reviews (Is It Legit And Safe Ingredients?) Can This Probiotic Really Transform Your Skin And Gut?
25/03/2025
BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- The Prime Biome probiotic supplement that has been garnering attention in the health supplement industry is a unique aid made with the intention of supporting the health of the [...]
Burning Rock Reports Unaudited Fourth Quarter and Full Year 2024 Financial Results
25/03/2025
GUANGZHOU, China, March 25, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in [...]
Cognition Therapeutics to Report Biomarker Results from Phase 2 SHINE Study in Mild-to-Moderate Alzheimer’s Disease in Podium Presentation at AD/PD 2025
25/03/2025
Additional Analyses to be Presented at AD/PD Include Correlation of CSF Biomarkers with Cognitive Outcomes, and Pharmacodynamic Biomarkers of Target Engagement PURCHASE, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- [...]
Enable Injections Announces Regulatory CE Mark Approval in Europe for enFuse Technology
25/03/2025
CINCINNATI, March 25, 2025 (GLOBE NEWSWIRE) -- Enable Injections, Inc. (“Enable”), a healthcare innovation company developing and manufacturing the enFuse ® wearable drug delivery platform, today announced it has [...]
Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases
25/03/2025
Target Indications Also Include Peeling Skin Syndrome, SAM Syndrome, Palmoplantar Keratoderma and Severe Atopic Dermatitis Third Quoin Patent Application for Netherton Syndrome If Granted Company Would have Patent [...]
Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.
25/03/2025
NDV-01 is a novel, sustained-release, intravesical gemcitabine/docetaxel, ready-for-use product candidate for the treatment of non-muscle invasive bladder cancer (NMIBC, U.S. prevalence of ~600,000 patients, with ~62, [...]
Traws Pharma’s COVID-19 Candidate, Ratutrelvir, Presented at ICAR
25/03/2025
Preclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimen Preparations are underway [...]
CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
25/03/2025
‒ Q4 2024 Net Revenue of $31.2mm; 2024 Net Revenue of $43.5mm ‒ ‒ Q4 Net Income of $13.5mm and Adjusted EBITDA of $15.3mm ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., March [...]
Aurora Spine Announces FDA 510(k) Clearance for the AERO™ Facet Fusion System
25/03/2025
CARLSBAD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a leader in innovative spine and interventional pain management solutions, [...]
Sanara MedTech Inc. Reports Fourth Quarter and Full Year 2024 Financial Results (Unaudited)
25/03/2025
Q4 Net Revenue Increased 49% Year-Over-Year; 2024 Net Revenue Increased 33% Year-Over-Year FORT WORTH, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” the “Company,” “we,” “our” or “us”) (Nasdaq: [...]
NMD Pharma presents preclinical data highlighting increased innervation of skeletal muscle with ClC-1 ion channel inhibition treatment in neuromuscular disease model
25/03/2025
Company presented clinical and preclinical data at the MDA Conference last week in Dallas, Texas Oral presentation included data from MuSK-MG rat model depicting increases in muscle function and improvements in the [...]
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025
25/03/2025
AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025 AC Immune to host symposium highlighting the company’s industry-leading pipeline of active immunotherapies for [...]

Pages